Why Concurrent CDDP and Radiotherapy Has Synergistic Antitumor Effects: A Review of In Vitro Experimental and Clinical-Based Studies
Chemo-radiotherapy, which combines chemotherapy with radiotherapy, has been clinically practiced since the 1970s, and various anticancer drugs have been shown to have a synergistic effect when used in combination with radiotherapy. In particular, cisplatin (CDDP), which is often the cornerstone of m...
Gespeichert in:
| Veröffentlicht in: | International journal of molecular sciences 2021-03, Vol.22 (6), p.3140, Article 3140 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 6 |
| container_start_page | 3140 |
| container_title | International journal of molecular sciences |
| container_volume | 22 |
| creator | Nagasawa, Shinsuke Takahashi, Junko Suzuki, Gen Hideya, Yamazaki Yamada, Kei |
| description | Chemo-radiotherapy, which combines chemotherapy with radiotherapy, has been clinically practiced since the 1970s, and various anticancer drugs have been shown to have a synergistic effect when used in combination with radiotherapy. In particular, cisplatin (CDDP), which is often the cornerstone of multi-drug combination cancer therapies, is highly versatile and frequently used in combination with radiotherapy for the treatment of many cancers. Therefore, the mechanisms underlying the synergistic effect of CDDP and radiotherapy have been widely investigated, although no definitive conclusions have been reached. We present a review of the combined use of CDDP and radiotherapy, including the latest findings, and propose a mechanism that could explain their synergistic effects. Our hypothesis involves the concepts of overlap and complementation. "Overlap" refers to the overlapping reactions of CDDP and radiation-induced excessive oxidative loading, which lead to accumulating damage to cell components, mostly within the cytoplasm. "Complementation" refers to the complementary functions of CDDP and radiation that lead to DNA damage, primarily in the nucleus. In fact, the two concepts are inseparable, but conceptualizing them separately will help us understand the mechanism underlying the synergism between radiation therapy and other anticancer drugs, and help us to design future radiosensitizers. |
| doi_str_mv | 10.3390/ijms22063140 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_webof</sourceid><recordid>TN_cdi_webofscience_primary_000645691900001CitationCount</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_680071240a424e208aa70eabe5653484</doaj_id><sourcerecordid>33808722</sourcerecordid><originalsourceid>FETCH-LOGICAL-c516t-66d51ee84b85eca2216e6f7275fa4a1b41f7128dc2091e85a1ce3422e2cd3463</originalsourceid><addsrcrecordid>eNqNks1vEzEQxVcIREvhxhn5DgF_rdfLASndBhqpEqit4Lia9c4mjjZ2ZDstufOHYxqI0hsnj-z3fuPxc1G8ZvS9EDX9YFfryDlVgkn6pDhlkvMJpap6elSfFC9iXFHKBS_r58WJEJrqivPT4teP5Y403pltCOgSaS4uvhFwPbmG3vq0xACbHbmESG52DsPCxmQNmbpk03btA5kNA5oUP5IpucY7i_fED2TuyHebgieznxsMdp3BMD5Qm9E6a2CcnEPEntykbW8xviyeDTBGfPV3PStuP89um8vJ1dcv82Z6NTElU2miVF8yRC07XaIBzplCNVS8KgeQwDrJhopx3RtOa4a6BGZQ5CdAbnohlTgr5nts72HVbvLFIOxaD7Z92PBh0ULI443YKk1pZkkKkkvkVANUFKHDUpVCaplZn_aszbZbY2_yiAHGR9DHJ84u24W_azNYlFRnwLs9wAQfY8Dh4GW0_RNsexxslr857ncQ_0syC_RecI-dH6Kx6AweZDT_AlmqmtW5oqyxCZL1rvFbl7L17f9bxW-tXcBx</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Why Concurrent CDDP and Radiotherapy Has Synergistic Antitumor Effects: A Review of In Vitro Experimental and Clinical-Based Studies</title><source>MEDLINE</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Nagasawa, Shinsuke ; Takahashi, Junko ; Suzuki, Gen ; Hideya, Yamazaki ; Yamada, Kei</creator><creatorcontrib>Nagasawa, Shinsuke ; Takahashi, Junko ; Suzuki, Gen ; Hideya, Yamazaki ; Yamada, Kei</creatorcontrib><description>Chemo-radiotherapy, which combines chemotherapy with radiotherapy, has been clinically practiced since the 1970s, and various anticancer drugs have been shown to have a synergistic effect when used in combination with radiotherapy. In particular, cisplatin (CDDP), which is often the cornerstone of multi-drug combination cancer therapies, is highly versatile and frequently used in combination with radiotherapy for the treatment of many cancers. Therefore, the mechanisms underlying the synergistic effect of CDDP and radiotherapy have been widely investigated, although no definitive conclusions have been reached. We present a review of the combined use of CDDP and radiotherapy, including the latest findings, and propose a mechanism that could explain their synergistic effects. Our hypothesis involves the concepts of overlap and complementation. "Overlap" refers to the overlapping reactions of CDDP and radiation-induced excessive oxidative loading, which lead to accumulating damage to cell components, mostly within the cytoplasm. "Complementation" refers to the complementary functions of CDDP and radiation that lead to DNA damage, primarily in the nucleus. In fact, the two concepts are inseparable, but conceptualizing them separately will help us understand the mechanism underlying the synergism between radiation therapy and other anticancer drugs, and help us to design future radiosensitizers.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms22063140</identifier><identifier>PMID: 33808722</identifier><language>eng</language><publisher>BASEL: Mdpi</publisher><subject><![CDATA[Animals ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biochemistry & Molecular Biology ; Chemistry ; Chemistry, Multidisciplinary ; chemo-radiotherapy (CRT) ; Chemoradiotherapy ; cis-diamminedichloroplatinum (cisplatin: CDDP) ; Cisplatin - administration & dosage ; Cisplatin - adverse effects ; Cisplatin - therapeutic use ; Clinical Studies as Topic ; Clinical Trials as Topic ; Combined Modality Therapy ; concurrent ; Drug Evaluation, Preclinical ; Humans ; Life Sciences & Biomedicine ; Neoplasms - diagnosis ; Neoplasms - etiology ; Neoplasms - mortality ; Neoplasms - therapy ; Physical Sciences ; Radiation-Sensitizing Agents - administration & dosage ; Radiation-Sensitizing Agents - adverse effects ; Radiation-Sensitizing Agents - therapeutic use ; radio-sensitizing ; radiotherapy (RT) ; Radiotherapy, Adjuvant - adverse effects ; Radiotherapy, Adjuvant - methods ; Review ; Science & Technology ; synergistic effect ; Treatment Outcome]]></subject><ispartof>International journal of molecular sciences, 2021-03, Vol.22 (6), p.3140, Article 3140</ispartof><rights>2021 by the authors. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>15</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000645691900001</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c516t-66d51ee84b85eca2216e6f7275fa4a1b41f7128dc2091e85a1ce3422e2cd3463</citedby><cites>FETCH-LOGICAL-c516t-66d51ee84b85eca2216e6f7275fa4a1b41f7128dc2091e85a1ce3422e2cd3463</cites><orcidid>0000-0001-7508-7217 ; 0000-0001-6018-468X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003508/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003508/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,886,27928,27929,39262,53795,53797</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33808722$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nagasawa, Shinsuke</creatorcontrib><creatorcontrib>Takahashi, Junko</creatorcontrib><creatorcontrib>Suzuki, Gen</creatorcontrib><creatorcontrib>Hideya, Yamazaki</creatorcontrib><creatorcontrib>Yamada, Kei</creatorcontrib><title>Why Concurrent CDDP and Radiotherapy Has Synergistic Antitumor Effects: A Review of In Vitro Experimental and Clinical-Based Studies</title><title>International journal of molecular sciences</title><addtitle>INT J MOL SCI</addtitle><addtitle>Int J Mol Sci</addtitle><description>Chemo-radiotherapy, which combines chemotherapy with radiotherapy, has been clinically practiced since the 1970s, and various anticancer drugs have been shown to have a synergistic effect when used in combination with radiotherapy. In particular, cisplatin (CDDP), which is often the cornerstone of multi-drug combination cancer therapies, is highly versatile and frequently used in combination with radiotherapy for the treatment of many cancers. Therefore, the mechanisms underlying the synergistic effect of CDDP and radiotherapy have been widely investigated, although no definitive conclusions have been reached. We present a review of the combined use of CDDP and radiotherapy, including the latest findings, and propose a mechanism that could explain their synergistic effects. Our hypothesis involves the concepts of overlap and complementation. "Overlap" refers to the overlapping reactions of CDDP and radiation-induced excessive oxidative loading, which lead to accumulating damage to cell components, mostly within the cytoplasm. "Complementation" refers to the complementary functions of CDDP and radiation that lead to DNA damage, primarily in the nucleus. In fact, the two concepts are inseparable, but conceptualizing them separately will help us understand the mechanism underlying the synergism between radiation therapy and other anticancer drugs, and help us to design future radiosensitizers.</description><subject>Animals</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biochemistry & Molecular Biology</subject><subject>Chemistry</subject><subject>Chemistry, Multidisciplinary</subject><subject>chemo-radiotherapy (CRT)</subject><subject>Chemoradiotherapy</subject><subject>cis-diamminedichloroplatinum (cisplatin: CDDP)</subject><subject>Cisplatin - administration & dosage</subject><subject>Cisplatin - adverse effects</subject><subject>Cisplatin - therapeutic use</subject><subject>Clinical Studies as Topic</subject><subject>Clinical Trials as Topic</subject><subject>Combined Modality Therapy</subject><subject>concurrent</subject><subject>Drug Evaluation, Preclinical</subject><subject>Humans</subject><subject>Life Sciences & Biomedicine</subject><subject>Neoplasms - diagnosis</subject><subject>Neoplasms - etiology</subject><subject>Neoplasms - mortality</subject><subject>Neoplasms - therapy</subject><subject>Physical Sciences</subject><subject>Radiation-Sensitizing Agents - administration & dosage</subject><subject>Radiation-Sensitizing Agents - adverse effects</subject><subject>Radiation-Sensitizing Agents - therapeutic use</subject><subject>radio-sensitizing</subject><subject>radiotherapy (RT)</subject><subject>Radiotherapy, Adjuvant - adverse effects</subject><subject>Radiotherapy, Adjuvant - methods</subject><subject>Review</subject><subject>Science & Technology</subject><subject>synergistic effect</subject><subject>Treatment Outcome</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>HGBXW</sourceid><sourceid>EIF</sourceid><sourceid>DOA</sourceid><recordid>eNqNks1vEzEQxVcIREvhxhn5DgF_rdfLASndBhqpEqit4Lia9c4mjjZ2ZDstufOHYxqI0hsnj-z3fuPxc1G8ZvS9EDX9YFfryDlVgkn6pDhlkvMJpap6elSfFC9iXFHKBS_r58WJEJrqivPT4teP5Y403pltCOgSaS4uvhFwPbmG3vq0xACbHbmESG52DsPCxmQNmbpk03btA5kNA5oUP5IpucY7i_fED2TuyHebgieznxsMdp3BMD5Qm9E6a2CcnEPEntykbW8xviyeDTBGfPV3PStuP89um8vJ1dcv82Z6NTElU2miVF8yRC07XaIBzplCNVS8KgeQwDrJhopx3RtOa4a6BGZQ5CdAbnohlTgr5nts72HVbvLFIOxaD7Z92PBh0ULI443YKk1pZkkKkkvkVANUFKHDUpVCaplZn_aszbZbY2_yiAHGR9DHJ84u24W_azNYlFRnwLs9wAQfY8Dh4GW0_RNsexxslr857ncQ_0syC_RecI-dH6Kx6AweZDT_AlmqmtW5oqyxCZL1rvFbl7L17f9bxW-tXcBx</recordid><startdate>20210319</startdate><enddate>20210319</enddate><creator>Nagasawa, Shinsuke</creator><creator>Takahashi, Junko</creator><creator>Suzuki, Gen</creator><creator>Hideya, Yamazaki</creator><creator>Yamada, Kei</creator><general>Mdpi</general><general>MDPI</general><general>MDPI AG</general><scope>BLEPL</scope><scope>DTL</scope><scope>HGBXW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-7508-7217</orcidid><orcidid>https://orcid.org/0000-0001-6018-468X</orcidid></search><sort><creationdate>20210319</creationdate><title>Why Concurrent CDDP and Radiotherapy Has Synergistic Antitumor Effects: A Review of In Vitro Experimental and Clinical-Based Studies</title><author>Nagasawa, Shinsuke ; Takahashi, Junko ; Suzuki, Gen ; Hideya, Yamazaki ; Yamada, Kei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c516t-66d51ee84b85eca2216e6f7275fa4a1b41f7128dc2091e85a1ce3422e2cd3463</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Animals</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biochemistry & Molecular Biology</topic><topic>Chemistry</topic><topic>Chemistry, Multidisciplinary</topic><topic>chemo-radiotherapy (CRT)</topic><topic>Chemoradiotherapy</topic><topic>cis-diamminedichloroplatinum (cisplatin: CDDP)</topic><topic>Cisplatin - administration & dosage</topic><topic>Cisplatin - adverse effects</topic><topic>Cisplatin - therapeutic use</topic><topic>Clinical Studies as Topic</topic><topic>Clinical Trials as Topic</topic><topic>Combined Modality Therapy</topic><topic>concurrent</topic><topic>Drug Evaluation, Preclinical</topic><topic>Humans</topic><topic>Life Sciences & Biomedicine</topic><topic>Neoplasms - diagnosis</topic><topic>Neoplasms - etiology</topic><topic>Neoplasms - mortality</topic><topic>Neoplasms - therapy</topic><topic>Physical Sciences</topic><topic>Radiation-Sensitizing Agents - administration & dosage</topic><topic>Radiation-Sensitizing Agents - adverse effects</topic><topic>Radiation-Sensitizing Agents - therapeutic use</topic><topic>radio-sensitizing</topic><topic>radiotherapy (RT)</topic><topic>Radiotherapy, Adjuvant - adverse effects</topic><topic>Radiotherapy, Adjuvant - methods</topic><topic>Review</topic><topic>Science & Technology</topic><topic>synergistic effect</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nagasawa, Shinsuke</creatorcontrib><creatorcontrib>Takahashi, Junko</creatorcontrib><creatorcontrib>Suzuki, Gen</creatorcontrib><creatorcontrib>Hideya, Yamazaki</creatorcontrib><creatorcontrib>Yamada, Kei</creatorcontrib><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Web of Science - Science Citation Index Expanded - 2021</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nagasawa, Shinsuke</au><au>Takahashi, Junko</au><au>Suzuki, Gen</au><au>Hideya, Yamazaki</au><au>Yamada, Kei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Why Concurrent CDDP and Radiotherapy Has Synergistic Antitumor Effects: A Review of In Vitro Experimental and Clinical-Based Studies</atitle><jtitle>International journal of molecular sciences</jtitle><stitle>INT J MOL SCI</stitle><addtitle>Int J Mol Sci</addtitle><date>2021-03-19</date><risdate>2021</risdate><volume>22</volume><issue>6</issue><spage>3140</spage><pages>3140-</pages><artnum>3140</artnum><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>Chemo-radiotherapy, which combines chemotherapy with radiotherapy, has been clinically practiced since the 1970s, and various anticancer drugs have been shown to have a synergistic effect when used in combination with radiotherapy. In particular, cisplatin (CDDP), which is often the cornerstone of multi-drug combination cancer therapies, is highly versatile and frequently used in combination with radiotherapy for the treatment of many cancers. Therefore, the mechanisms underlying the synergistic effect of CDDP and radiotherapy have been widely investigated, although no definitive conclusions have been reached. We present a review of the combined use of CDDP and radiotherapy, including the latest findings, and propose a mechanism that could explain their synergistic effects. Our hypothesis involves the concepts of overlap and complementation. "Overlap" refers to the overlapping reactions of CDDP and radiation-induced excessive oxidative loading, which lead to accumulating damage to cell components, mostly within the cytoplasm. "Complementation" refers to the complementary functions of CDDP and radiation that lead to DNA damage, primarily in the nucleus. In fact, the two concepts are inseparable, but conceptualizing them separately will help us understand the mechanism underlying the synergism between radiation therapy and other anticancer drugs, and help us to design future radiosensitizers.</abstract><cop>BASEL</cop><pub>Mdpi</pub><pmid>33808722</pmid><doi>10.3390/ijms22063140</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0001-7508-7217</orcidid><orcidid>https://orcid.org/0000-0001-6018-468X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1422-0067 |
| ispartof | International journal of molecular sciences, 2021-03, Vol.22 (6), p.3140, Article 3140 |
| issn | 1422-0067 1661-6596 1422-0067 |
| language | eng |
| recordid | cdi_webofscience_primary_000645691900001CitationCount |
| source | MEDLINE; MDPI - Multidisciplinary Digital Publishing Institute; Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Animals Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biochemistry & Molecular Biology Chemistry Chemistry, Multidisciplinary chemo-radiotherapy (CRT) Chemoradiotherapy cis-diamminedichloroplatinum (cisplatin: CDDP) Cisplatin - administration & dosage Cisplatin - adverse effects Cisplatin - therapeutic use Clinical Studies as Topic Clinical Trials as Topic Combined Modality Therapy concurrent Drug Evaluation, Preclinical Humans Life Sciences & Biomedicine Neoplasms - diagnosis Neoplasms - etiology Neoplasms - mortality Neoplasms - therapy Physical Sciences Radiation-Sensitizing Agents - administration & dosage Radiation-Sensitizing Agents - adverse effects Radiation-Sensitizing Agents - therapeutic use radio-sensitizing radiotherapy (RT) Radiotherapy, Adjuvant - adverse effects Radiotherapy, Adjuvant - methods Review Science & Technology synergistic effect Treatment Outcome |
| title | Why Concurrent CDDP and Radiotherapy Has Synergistic Antitumor Effects: A Review of In Vitro Experimental and Clinical-Based Studies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T13%3A36%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_webof&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Why%20Concurrent%20CDDP%20and%20Radiotherapy%20Has%20Synergistic%20Antitumor%20Effects:%20A%20Review%20of%20In%20Vitro%20Experimental%20and%20Clinical-Based%20Studies&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Nagasawa,%20Shinsuke&rft.date=2021-03-19&rft.volume=22&rft.issue=6&rft.spage=3140&rft.pages=3140-&rft.artnum=3140&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms22063140&rft_dat=%3Cpubmed_webof%3E33808722%3C/pubmed_webof%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/33808722&rft_doaj_id=oai_doaj_org_article_680071240a424e208aa70eabe5653484&rfr_iscdi=true |